François-Xavier Mahon
Laboratoire d'Hématologie et Service des Maladies du Sang
Centre Hospitalier Universitaire de Bordeaux
Bordeaux
France
Name/email consistency: high
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J., Rousselot, P. Lancet Oncol. (2010)
- Pharmacologic monitoring and determinants of intracytoplasmic drug levels. Mahon, F.X. Best. Pract. Res. Clin. Haematol (2009)
- JAK the trigger. Mahon, F.X. Oncogene (2005)
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Mahon, F.X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J.M., Melo, J.V. Blood (2003)